These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1973358)

  • 1. The relationship between multidrug resistance and tumor necrosis factor resistance in an EL4 cell line model.
    Ujhazy P; Chen YF; Fredericks W; Ho RL; Mihich E; Baker RM; Ehrke MJ
    Cancer Commun; 1990; 2(5):181-8. PubMed ID: 1973358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity of drug-resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-alpha) and doxorubicin: failure of the combination to modulate the MDR phenotype.
    Safrit JT; Berek JS; Bonavida B
    Gynecol Oncol; 1993 Feb; 48(2):214-20. PubMed ID: 8428693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to TNF-alpha and adriamycin in the human breast cancer MCF-7 cell line: relationship to MDR1, MnSOD, and TNF gene expression.
    Zyad A; Bénard J; Tursz T; Clarke R; Chouaib S
    Cancer Res; 1994 Feb; 54(3):825-31. PubMed ID: 7905787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
    Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H
    Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T; Lübbert M; Martens C; Bross KJ; Fiebig HH; Mertelsmann R; Herrmann F
    Cytokines Mol Ther; 1995 Jun; 1(2):123-32. PubMed ID: 9384669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression.
    Slapak CA; Daniel JC; Levy SB
    Cancer Res; 1990 Dec; 50(24):7895-901. PubMed ID: 1979251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines.
    Ford JM; Bruggemann EP; Pastan I; Gottesman MM; Hait WN
    Cancer Res; 1990 Mar; 50(6):1748-56. PubMed ID: 1968358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Synergistic effect of bromocriptine combining tumor necrosis factor-alpha on reversing multidrug resistance in a nude mouse model of liver neoplasm].
    Ding L; Chen XP; Zhang ZW; Wang H; Cao B; Wang ZH; Li CL
    Zhonghua Wai Ke Za Zhi; 2005 Oct; 43(19):1248-53. PubMed ID: 16271222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro multidrug resistance of P388 murine leukemia selected for resistance to diaziquone.
    Gutierrez PL; Wilder PJ; Biswal N
    Cancer Commun; 1989; 1(3):181-90. PubMed ID: 2576972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined activity of interleukin-1 alpha or TNF-alpha and doxorubicin on multidrug resistant cell lines: evidence that TNF and DXR have synergistic antitumor and differentiation-inducing effects.
    Borsellino N; Crescimanno M; Flandina C; Flugy A; D'Alessandro N
    Anticancer Res; 1994; 14(6B):2643-8. PubMed ID: 7872695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
    Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
    Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
    Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
    Hill AB; Beck WT; Trent JM
    Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance.
    Ho SB; Yan PS; Dahiya R; Neuschwander-Tetri BA; Basbaum C; Kim YS
    J Cell Physiol; 1994 Aug; 160(2):213-26. PubMed ID: 7913708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
    Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210.
    Volm M; Mattern J; Pommerenke EW
    Anticancer Res; 1991; 11(2):579-85. PubMed ID: 1676579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
    Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
    Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
    Morimoto H; Yonehara S; Bonavida B
    Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening.
    Wu L; Smythe AM; Stinson SF; Mullendore LA; Monks A; Scudiero DA; Paull KD; Koutsoukos AD; Rubinstein LV; Boyd MR
    Cancer Res; 1992 Jun; 52(11):3029-34. PubMed ID: 1350507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis.
    Jazirehi AR; Ng CP; Gan XH; Schiller G; Bonavida B
    Clin Cancer Res; 2001 Dec; 7(12):3874-83. PubMed ID: 11751478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.